Testing Proceeds for Possible Celiac Disease Drug
BALTIMORE, May 7 /PRNewswire/ — Alba Therapeutics Corporation today announced preliminary results from its Phase IIa clinical trial for AT-1001 in subjects with Celiac Disease (CD), an autoimmune disease affecting over 3 million people in the United States. Alba’s study, the first Phase IIa trial in CD and the first to assess dosing [...]
http://myceliacblog.com/archives/27
